RU2602062C2 - Кристаллическая форма циклоспорина а, способы ее получения и способы применения - Google Patents
Кристаллическая форма циклоспорина а, способы ее получения и способы применения Download PDFInfo
- Publication number
- RU2602062C2 RU2602062C2 RU2013155033/04A RU2013155033A RU2602062C2 RU 2602062 C2 RU2602062 C2 RU 2602062C2 RU 2013155033/04 A RU2013155033/04 A RU 2013155033/04A RU 2013155033 A RU2013155033 A RU 2013155033A RU 2602062 C2 RU2602062 C2 RU 2602062C2
- Authority
- RU
- Russia
- Prior art keywords
- crystalline form
- cyclosporin
- eye
- dry
- ophthalmologically acceptable
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 52
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 48
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 229960001265 ciclosporin Drugs 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 18
- 206010013774 Dry eye Diseases 0.000 claims description 17
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 13
- 206010046851 Uveitis Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000007812 deficiency Effects 0.000 claims description 7
- 206010023332 keratitis Diseases 0.000 claims description 7
- 206010014801 endophthalmitis Diseases 0.000 claims description 6
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 abstract description 10
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical group [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 208000030533 eye disease Diseases 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 239000007943 implant Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 24
- 201000000760 cerebral cavernous malformation Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000004087 cornea Anatomy 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 229930182912 cyclosporin Natural products 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000004561 lacrimal apparatus Anatomy 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000000607 artificial tear Substances 0.000 description 4
- 230000004397 blinking Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 210000003560 epithelium corneal Anatomy 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 206010022941 Iridocyclitis Diseases 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000004612 anterior uveitis Diseases 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- PJDINCOFOROBQW-LURJTMIESA-N (3S)-3,7-diaminoheptanoic acid Chemical compound NCCCC[C@H](N)CC(O)=O PJDINCOFOROBQW-LURJTMIESA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010036941 Cyclosporins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- -1 immunoglobulin A Substances 0.000 description 2
- 229940099472 immunoglobulin a Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010023365 keratopathy Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- WPRAXAOJIODQJR-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C(C)=C1 WPRAXAOJIODQJR-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 0 CC(*)C[C@@](C(N*)=O)N(*)C(C(C)NC([C@](C)NC([C@](CC(C)N)N(C)C([C@](C(C)*)NC([C@](CC(*)*)N(C)C(CN(*)C([C@](C*)C=CNC(C([C@@]([C@](C)CC=CC)O)N(*)C([C@](C(C)*)N(C)COC)=*)=O)=C1CC1)=O)=O)=*=C)=O)=O)=O Chemical compound CC(*)C[C@@](C(N*)=O)N(*)C(C(C)NC([C@](C)NC([C@](CC(C)N)N(C)C([C@](C(C)*)NC([C@](CC(*)*)N(C)C(CN(*)C([C@](C*)C=CNC(C([C@@]([C@](C)CC=CC)O)N(*)C([C@](C(C)*)N(C)COC)=*)=O)=C1CC1)=O)=O)=*=C)=O)=O)=O 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical group O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490887P | 2011-05-27 | 2011-05-27 | |
| US61/490,887 | 2011-05-27 | ||
| PCT/US2012/039611 WO2012166610A1 (en) | 2011-05-27 | 2012-05-25 | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013155033A RU2013155033A (ru) | 2015-07-20 |
| RU2602062C2 true RU2602062C2 (ru) | 2016-11-10 |
Family
ID=46178866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013155033/04A RU2602062C2 (ru) | 2011-05-27 | 2012-05-25 | Кристаллическая форма циклоспорина а, способы ее получения и способы применения |
Country Status (19)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766160C2 (ru) * | 2017-05-17 | 2022-02-08 | Юю Фарма, Инк. | Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2779994T3 (da) * | 2011-11-15 | 2020-05-18 | Allergan Inc | Suspensioner af cyclosporin a form 2 |
| AU2012339695B2 (en) * | 2011-11-15 | 2017-10-05 | Allergan, Inc. | Sustained action formulation of cyclosporin Form 2 |
| RU2635547C2 (ru) | 2011-11-15 | 2017-11-14 | Аллерган, Инк. | Форма 2 циклоспорина а и способ ее получения |
| WO2013074616A1 (en) * | 2011-11-15 | 2013-05-23 | Allergan, Inc. | Autoclavable suspensions of cyclosporin a form 2 |
| CN104487449A (zh) | 2012-06-01 | 2015-04-01 | 阿勒根公司 | 环孢菌素a类似物 |
| GB201222455D0 (en) * | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| US10524661B2 (en) * | 2013-06-12 | 2020-01-07 | Proactive Live, Inc. | Sleep monitoring and stimulation |
| AU2015289387B2 (en) | 2014-07-18 | 2020-10-22 | Allergan, Inc. | Suspension compositions of cyclosporin A for subconjunctival and periocular injection |
| WO2016112321A1 (en) | 2015-01-08 | 2016-07-14 | Allergan, Inc. | Cyclosporin derivatives wherein the mebmt sidechain has been cyclized |
| US10443292B2 (en) * | 2016-04-25 | 2019-10-15 | Magna Closures, Inc. | Non-contact obstacle detection system for motor vehicles |
| US11613558B2 (en) | 2018-11-14 | 2023-03-28 | Yuyu Pharma, Inc. | Peptides and pharmaceutical compositions for treating eye diseases |
| KR20250088544A (ko) | 2022-10-20 | 2025-06-17 | 추가이 세이야쿠 가부시키가이샤 | 고리형 펩티드 결정을 제조하는 방법 |
| JPWO2024195801A1 (cg-RX-API-DMAC7.html) | 2023-03-20 | 2024-09-26 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2211848A (en) * | 1987-12-21 | 1989-07-12 | Sandoz Ltd | Orthorhomic ciclosporin crystals |
| RU2098122C1 (ru) * | 1991-03-18 | 1997-12-10 | Сандос АГ | Фармацевтическая композиция для лечения воспалительных заболеваний или заболеваний, связанных с обструкцией дыхательных путей |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| CN101687013A (zh) * | 2007-05-04 | 2010-03-31 | 阿勒根公司 | 环孢菌素在治疗具有人工晶状体的患者中的用途 |
| BRPI0822221A2 (pt) * | 2008-01-04 | 2015-06-23 | Alcon Pharmaceuticals Ltd | Composições aquosas e estáveis de ciclosporina |
-
2012
- 2012-05-25 WO PCT/US2012/039611 patent/WO2012166610A1/en not_active Ceased
- 2012-05-25 AU AU2012262513A patent/AU2012262513B2/en not_active Ceased
- 2012-05-25 EP EP18211911.5A patent/EP3521302A1/en not_active Withdrawn
- 2012-05-25 UA UAA201314231A patent/UA113627C2/uk unknown
- 2012-05-25 RU RU2013155033/04A patent/RU2602062C2/ru active
- 2012-05-25 CA CA2836946A patent/CA2836946C/en active Active
- 2012-05-25 CN CN201280033382.7A patent/CN103649108B/zh active Active
- 2012-05-25 BR BR112013030554-1A patent/BR112013030554B1/pt active IP Right Grant
- 2012-05-25 MY MYPI2013004226A patent/MY180581A/en unknown
- 2012-05-25 SG SG10201607344UA patent/SG10201607344UA/en unknown
- 2012-05-25 KR KR1020137034444A patent/KR102079402B1/ko not_active Expired - Fee Related
- 2012-05-25 US US13/480,710 patent/US8772245B2/en active Active
- 2012-05-25 EP EP12724525.6A patent/EP2714720B1/en active Active
- 2012-05-25 MX MX2013013855A patent/MX362271B/es active IP Right Grant
- 2012-05-25 JP JP2014512145A patent/JP6163482B2/ja active Active
- 2012-05-28 TW TW101119051A patent/TWI554522B/zh not_active IP Right Cessation
- 2012-05-28 AR ARP120101878A patent/AR086586A1/es not_active Application Discontinuation
-
2013
- 2013-11-17 IL IL229475A patent/IL229475A0/en unknown
- 2013-11-19 ZA ZA2013/08665A patent/ZA201308665B/en unknown
- 2013-11-26 CL CL2013003400A patent/CL2013003400A1/es unknown
-
2014
- 2014-07-02 US US14/322,475 patent/US9206228B2/en active Active
-
2015
- 2015-12-07 US US14/961,132 patent/US20160083432A1/en not_active Abandoned
-
2016
- 2016-06-15 AU AU2016203990A patent/AU2016203990A1/en not_active Abandoned
-
2017
- 2017-11-21 AU AU2017265008A patent/AU2017265008A1/en not_active Abandoned
-
2019
- 2019-06-14 AU AU2019204192A patent/AU2019204192B2/en not_active Ceased
-
2021
- 2021-01-13 US US17/148,315 patent/US20210269484A1/en not_active Abandoned
-
2022
- 2022-01-27 IL IL290158A patent/IL290158A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2211848A (en) * | 1987-12-21 | 1989-07-12 | Sandoz Ltd | Orthorhomic ciclosporin crystals |
| RU2098122C1 (ru) * | 1991-03-18 | 1997-12-10 | Сандос АГ | Фармацевтическая композиция для лечения воспалительных заболеваний или заболеваний, связанных с обструкцией дыхательных путей |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766160C2 (ru) * | 2017-05-17 | 2022-02-08 | Юю Фарма, Инк. | Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2602062C2 (ru) | Кристаллическая форма циклоспорина а, способы ее получения и способы применения | |
| AU759753B2 (en) | Ocular treatment using cyclosporin-A derivatives | |
| RU2639393C2 (ru) | Состав пролонгированного действия циклоспорина формы 2 | |
| RU2641963C2 (ru) | Взвеси циклоспорина а формы 2 | |
| JP2009501727A (ja) | 巨大分子集合体の存在に関連した状態、特に眼科障害の治療 | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| JP2008533000A (ja) | ＴＧＦ−βに対する抗体を含むアベリノ角膜ジストロフィー治療用医薬組成物 | |
| KR20210127872A (ko) | 안과 질환의 치료를 위한 킬레이트제, 침투 증강제 및 히드록시에틸 셀룰로스를 포함하는 제제 | |
| CN115884782A (zh) | 新型干眼症治疗用药物组合物 | |
| NZ618213B2 (en) | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof | |
| NZ719272B2 (en) | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof | |
| HK1193117A (en) | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof | |
| HK1193117B (en) | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof | |
| WO2023160499A1 (zh) | 一种肽、含有所述肽的眼用药物组合物及其用途 | |
| HK1202066B (en) | Suspensions of cyclosporin a form 2 |